Reuters logo
BRIEF-EU Medicines Agency recommends approval of Boehringer Ingelheim's Adalimumab drug
September 15, 2017 / 11:52 AM / 2 months ago

BRIEF-EU Medicines Agency recommends approval of Boehringer Ingelheim's Adalimumab drug

Sept 15 (Reuters) - EU Medicines Agency:

* EU Medicines Agency recommends approval of Boehringer Ingelheim International’s Cyltezo (Adalimumab) drug for treatment of multiple diseases including rheumatoid arthritis

* EU Medicines Agency recommends approval of Samsung Bioepis UK Ltd (SBUK) trastuzumab drug for treatment of breast cancer and metastatic gastric cancer‍​ Source text ID: (bit.ly/2vYqmaD)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below